Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C

NCT04666298 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

312

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia
Heterozygous Familial Hypercholesterolemia

Interventions

DRUG: Inclisiran sodium
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals